Recent corporate developments include a reverse stock split and a memorandum of understanding with Element Global, Inc. The company has also been involved in investment committee formation announcements related to Element Acquisition Corporation.

• BioForce Nanosciences Holdings, Inc. announced a 1-for-5 reverse stock split effective February 28, 2020 [N3].
• Element Global, Inc. announced signing a memorandum of understanding with BioForce Nanosciences Holdings, Inc. in June 2021 [N1].
• Element Acquisition Corporation announced the formation of its investment committee in June 2020, which is related to the broader corporate context [N2].

The company’s mission to provide natural nutritional supplements aligns with growing consumer interest in health and wellness. The signing of a memorandum of understanding with Element Global, Inc. may provide strategic partnership opportunities. Management’s commitment to securing additional funding could support continued operations and potential business development.

BioForce Nanosciences has not generated revenue from its core products in recent years and reports significant net losses and liquidity deficits. The company’s ability to continue operations depends heavily on raising additional capital, with substantial doubt expressed about its going concern status. Failure to secure funding or generate sales could lead to cessation or major restructuring of operations.

The company operates in the nutritional supplements sector, which is competitive and fragmented. There is no disclosed proprietary technology or significant competitive advantage detailed in the filings. The lack of product sales and ongoing financial losses limit evidence of a sustainable moat.

• Going Concern Risk: The company has substantial accumulated deficits and working capital deficits, with very limited cash relative to liabilities, raising significant doubt about its ability to continue as a going concern without additional financing.
• Revenue Generation Risk: No revenue was reported from product sales in recent years, indicating challenges in commercializing its nutritional supplements.
• Liquidity Risk: Current liquidity ratios are extremely low, indicating potential difficulties in meeting short-term obligations.
• Dependence on Financing: The company’s operations and business plan execution depend on its ability to raise additional debt or equity financing, with no assurance of success.

• BioForce Nanosciences Holdings, Inc. aims to be a leading provider of natural vitamins, minerals, and nutritional supplements, including powders and beverages, targeting active individuals across all age ranges.
• The company had no revenue from sales of its vitamin supplements for the years ended December 31, 2024 and 2025, with zero unit sales of its 'BioForce Eclipse' supplement product during those periods.
• As of December 31, 2025, the company had total assets of $786 and total liabilities of $618,522, resulting in a working capital deficit of $618,543 and an accumulated deficit exceeding $162 million.
• The company reported net losses of $1,291,951 for the year ended December 31, 2025, and $490,437 for the year ended December 31, 2024, with the increase in loss primarily due to a loss on liability settlement of approximately $801,193.
• Cash and cash equivalents as of March 31, 2026, were $6,347, with current liabilities of $727,301, resulting in a current ratio and cash ratio of approximately 0.01, indicating very limited liquidity.
• The company is dependent on additional debt and equity financing to continue operations and implement its business plan, with an oral commitment from its Chairman to provide necessary funds for the next 12 months.
• BioForce Nanosciences has undertaken a 1-for-5 reverse stock split effective February 28, 2020.
• The company has signed a memorandum of understanding (MOU) with Element Global, Inc. as announced in June 2021.
• The company follows ASC Topic 606 for revenue recognition and ASC Topic 718 for stock-based compensation accounting.
• There are no material pending legal proceedings against the company as of the latest filings.